Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals has successfully raised C$44.5 million through a non-brokered private placement of preferred shares to support its clinical trials and other corporate initiatives. Additionally, the company strengthened its board with the appointment of Joseph Freedman, a seasoned private equity investor.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
